文献速递眼底病与葡萄膜炎

全球妊娠期原有糖尿病女性糖尿病视网膜病变患病率与进展率的系统评价与Meta分析

Global Estimates of Diabetic Retinopathy Prevalence and Progression in Pregnant Women With Preexisting Diabetes: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Ophthalmol · 2022-01-01

该系统评价与Meta分析纳入18项观察性研究,包括1464例妊娠期1型糖尿病(T1D)女性和262例2型糖尿病(T2D)女性,估算孕早期任何糖尿病视网膜病变(DR)和增殖性DR(PDR)的合并患病率分别为52.3/100次妊娠和6.1/100次妊娠;T1D与T2D组的DR进展率相似,但新发DR在T1D组为15.8/100次妊娠、T2D组为9.0/100次妊娠;1989年圣文森特宣言后全球DR进展率呈下降趋势。

要点

  • 孕早期任何DR合并患病率为52.3/100次妊娠(95%CI 41.9-62.6),PDR为6.1/100次妊娠(95%CI 3.1-9.8)。
  • 非增殖性DR恶化进展率为31.0/100次妊娠(95%CI 23.2-39.2),从非增殖性DR进展为PDR为6.3/100次妊娠(95%CI 3.3-10.0)。
  • T1D与T2D组的DR进展率相似,但新发DR在T1D组为15.8/100次妊娠(95%CI 10.5-21.9),T2D组为9.0/100次妊娠(95%CI 4.9-14.8)。

核心结论

  • 该系统评价与Meta分析提示,T1D和T2D女性在妊娠期间DR进展风险相似;尽管糖尿病及其妊娠期管理有所改善,妊娠期糖尿病女性的DR患病率和进展率仍高于非妊娠糖尿病女性,突显改善妊娠期DR管理的需要。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE/Ovid、Embase/Ovid和Scopus数据库,纳入18项观察性研究,包括1464例妊娠期T1D女性和262例妊娠期T2D女性;采用随机效应模型和Freeman-Tukey双反正弦变换合并数据,遵循MOOSE报告指南。

主要发现

  • 孕早期任何DR合并患病率为52.3/100次妊娠(95%CI 41.9-62.6),PDR为6.1/100次妊娠(95%CI 3.1-9.8)。
  • 新发DR合并进展率为15.0/100次妊娠(95%CI 9.9-20.8),非增殖性DR恶化进展率为31.0/100次妊娠(95%CI 23.2-39.2)。
  • 从非增殖性DR进展为PDR的进展率为6.3/100次妊娠(95%CI 3.3-10.0),PDR恶化进展率为37.0/100次妊娠(95%CI 21.2-54.0)。
  • T1D与T2D组的DR进展率相似,但新发DR在T1D组为15.8/100次妊娠(95%CI 10.5-21.9),T2D组为9.0/100次妊娠(95%CI 4.9-14.8)。
  • 1989年圣文森特宣言后观察到全球DR进展率呈下降趋势。

关键数值与推荐

  • 任何DR合并患病率为52.3/100次妊娠(95%CI 41.9-62.6)。
  • PDR合并患病率为6.1/100次妊娠(95%CI 3.1-9.8)。
  • 新发DR合并进展率为15.0/100次妊娠(95%CI 9.9-20.8),非增殖性DR恶化进展率为31.0/100次妊娠(95%CI 23.2-39.2)。
  • 从非增殖性DR进展为PDR的进展率为6.3/100次妊娠(95%CI 3.3-10.0),PDR恶化进展率为37.0/100次妊娠(95%CI 21.2-54.0)。
  • 新发DR在T1D组为15.8/100次妊娠(95%CI 10.5-21.9),T2D组为9.0/100次妊娠(95%CI 4.9-14.8)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Diabetic retinopathy (DR) may be worsened by pregnancy in pregnant women with preexisting type 1 diabetes (T1D) or type 2 diabetes (T2D). Conflicting findings from previous studies have resulted in inconsistencies in guidelines regarding DR management in pregnancy. Global estimates of DR prevalence and progression in pregnancy are therefore required to provide clearer information about the overall true burden of DR in this population. OBJECTIVE: To estimate the prevalence of DR and its progression rate in pregnant women with preexisting T1D or T2D diagnosed before pregnancy. DATA SOURCES: For this systematic review and meta-analysis, conducted from November 27, 2018, to June 29, 2021, a systematic literature search was conducted in MEDLINE/Ovid, Embase/Ovid, and Scopus databases to identify English-language articles that were published from inception through October 2020. STUDY SELECTION: Observational studies that reported on DR and its changes in pregnant women with preexisting T1D and T2D. DATA EXTRACTION AND SYNTHESIS: Two independent reviewers extracted relevant data from each included study. Data were pooled using a random-effects model with the Freeman-Tukey double arcsine transformation. This study followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines. MAIN OUTCOMES AND MEASURES: Prevalence of any DR, proliferative DR (PDR), and DR progression rates. RESULTS: A total of 18 observational studies involving 1464 pregnant women with T1D and 262 pregnant women with T2D were included in the analysis. The pooled prevalence of any DR and PDR in early pregnancy was 52.3 (95% CI, 41.9-62.6) and 6.1 (95% CI, 3.1-9.8) per 100 pregnancies, respectively. The pooled progression rate per 100 pregnancies for new DR development was 15.0 (95% CI, 9.9-20.8), worsened nonproliferative DR was 31.0 (95% CI, 23.2-39.2), progression from nonproliferative DR to PDR was 6.3 (95% CI, 3.3-10.0), and worsened PDR was 37.0 (95% CI, 21.2-54.0). DR progression rates per 100 pregnancies were similar between the T1D and T2D groups, except for the development of new DR (T1D groups: 15.8; 95% CI, 10.5-21.9; T2D groups: 9.0; 95% CI, 4.9-14.8). A global trend toward a lower DR progression rate was observed after the 1989 St Vincent Declaration. CONCLUSIONS AND RELEVANCE: Results of this systematic review and meta-analysis suggest that women with T1D and T2D had a similar risk of DR progression during pregnancy. Despite improvements in the management of diabetes and diabetes during pregnancy, DR prevalence and progression in pregnant women with diabetes remains higher than the nonpregnant population with diabetes, highlighting the need to improve DR management in pregnancy.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Widyaputri F, Rogers SL, Kandasamy R, et al. Global Estimates of Diabetic Retinopathy Prevalence and Progression in Pregnant Women With Preexisting Diabetes: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2022. PMID: 35357410. doi:10.1001/jamaophthalmol.2022.0050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。